Prognostic role of CHEK2, FASN and Her2/neu Expression in Stage Ta-T1 Non-Muscle-Invasive Bladder Cancer (NMIBC).

Background: Though linked with a favorable overall survival rate, the heterogeneity of NMIBC (non-muscle invasive bladder cancer) has an effect on patients' rates of recurrence. The decision making is depended on the established pathological and clinical parameters for each individual. Therefore, to improve clinical outcome, life quality and survival rates of oncological patients, more parameters are needed to support the decision. Objectives: Analysis the prognostic potential of CHEK2, FASN and Her2/neu immunohistochemical expression in fifty cases of non-muscle invasive bladder cancer who underwent TURBT as well as adjuvant intravesical BCG with a focus on prognostication of recurrence as well as progression among NMIBC. Materials and Methods: Our study included fifty cases who had primary papillary superficial (noninvasive) TCC "transitional cell carcinoma" (Stage Ta-T1; with or without CIS of the bladder. Only the tumors containing proper detrusor muscle in biopsy were involved in this study. Between January 2016 and December 2019, the Urology department performed surgical resection. Results: Decrease or loss of CHE2 expression was reported among (56%) of the patients, which was significantly linked with tumor size, smoking, grade, multifocality and concomitant Cis. High FASN expression was demonstrated among (68%) NMIBC cases, expression was significantly linked with tumor size, smoking, grade, multifocality as well concomitant Cis. Positive Her2/neu was found in of (42%) the cases, and the expression was significantly linked with tumor size, smoking, grade, multifocality and concomitant carcinoma in situ. The overall disease-free survival was significantly correlated with low expression of CHEK2 and positive Her2neu. Conclusion: Loss of CHEK2, high FASN and positive Her2/neu in the biopsies of noninvasive "superficial" urothelial carcinomas is an independent predictor of tumor progression. [ABSTRACT FROM AUTHOR]